Association of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 with estimated glomerular filtration rate in patients with type 2 diabetes mellitus

Sheng Jiang^†*, Jing Yang^†

Show Less

¹ State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Department of Endocrinology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830 017, China

Global Translational Medicine 2022, 1(2), 62 https://doi.org/10.36922/gtm.v1i2.62

Submitted: 8 April 2022 | Revised: 30 August 2022 | Published: 21 September 2022

© 2022 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Abstract

Type 2 diabetes mellitus patients often suffer from kidney damage, which is more serious than in ordinary people. The insulin-like growth factor (IGF) system has synergistic effects with other hormonal axes and has an essential role in glucose metabolism and type 2 diabetes. The study aimed to observe the association of IGF-1 and IGF factor-binding protein-3 (IGFBP-3) with estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes mellitus. We recruited 521 patients with type 2 diabetes from the Endocrinology Department of the First Affiliated Hospital of Xinjiang Medical University from March 1, 2021, to December 20, 2021. The clinical data we collected were analyzed to determine the association of IGF-1 and IGFBP-3 with eGFR in patients with type 2 diabetes. Spearman correlation analysis showed that eGFR was positively correlated with IGF-1 and IGFBP-3 in all subjects (P = 0.044 and P = 0.004, respectively). We developed a linear regression model. In the multiple linear regression model, serum IGF-1 and IGFBP-3 were positively correlated with eGFR (β = 0.03, 95% CI = 0.01 – 0.06; P = 0.009 and β = 1.29, 95% CI = 0.09 – 2.49; P = 0.035). The results of the correlations were further validated. This preliminary study demonstrated positive associations of serum IGF-1 and IGFBP-3 levels with eGFR in patients with type 2 diabetes.

Keywords

Estimated glomerular filtration rate

Insulin-like growth factor-binding protein-3

Insulin-like growth factor-1

Kidney function

Type 2 diabetes mellitus

Funding

State Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia

Conflict of interest

The authors report no conflicts of interest in this work

References

[1]

Petersmann A, Muller-Wieland D, Muller UA, et al., 2019, Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes, 127: S1–S7. https://doi.org/10.1055/a-1018-9078

[2]

Compston J, 2018, Type 2 diabetes mellitus and bone. J Intern Med, 283: 140–153. https://doi.org/10.1111/joim.12725

[3]

Thomas MC, Brownlee M, Susztak K, et al., 2015, Diabetic kidney disease. Nat Rev Dis Primers, 1: 15018. https://doi.org/10.1038/nrdp.2015.18

[4]

Kramer HJ, Nguyen QD, Curhan G, et al., 2003, Renal insufficiency in the absence of albuminuria and retinopathy among adults with Type 2 diabetes mellitus. JAMA, 289: 3273–3277. https://doi.org/10.1001/jama.289.24.3273

[5]

Garg AX, Kiberd BA, Clark WF, et al., 2002, Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III. Kidney Int, 61: 2165–2175. https://doi.org/10.1046/j.1523-1755.2002.00356.x

[6]

MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al., 2007, Nonalbuminuric renal insufficiency in Type 2 diabetes. Diabetes Care, 27: 195–200. https://doi.org/10.2337/diacare.27.1.195

[7]

Rahmani J, Montesanto A, Giovannucci E, et al., 2022, Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis. Aging Cell, 21: e13540. https://doi.org/10.1111/acel.13540

[8]

Liu H, Gu H, Kutbi EH, et al., 2021, Association of IGF-1 and IGFBP-3 levels with gastric cancer: A systematic review and meta-analysis. Int J Clin Pract, 75: e14764. https://doi.org/10.1111/ijcp.14764

[9]

Qiang J, Kai L, Lulu H, et al., 2020, The effect of resistance training on serum insulin-like growth factor 1(IGF-1): A systematic review and meta-analysis. Complement Ther Med, 50: 102360. https://doi.org/10.1016/j.ctim.2020.102360

[10]

Aguirre GA, Gonzalez-Guerra JL, Espinosa L, et al., 2018, Insulin-like growth factor 1 in the cardiovascular system. Rev Physiol Biochem Pharmacol, 175: 1–45. https://doi.org/10.1007/112_2017_8

[11]

Nambam B, Schatz D, 2018, Growth hormone and insulin-like growth factor-I axis in Type 1 diabetes. Growth Horm IGF Res, 38: 49–52. https://doi.org/10.1016/j.ghir.2017.12.005

[12]

Akcali A, Bal B, Erbagci B, 2017, Circulating IGF-1, IGFB-3, GH and TSH levels in multiple sclerosis and their relationship with treatment. Neurol Res, 39: 606–611. https://doi.org/10.1080/01616412.2017.1321711

[13]

Gatti R, De Palo E F, Antonelli G, et al., 2012, IGF-I/ IGFBP system: Metabolism outline and physical exercise. J Endocrinol Invest, 35: 699–707. https://doi.org/10.3275/8456

[14]

Ranke MB, 2015, Insulin-like growth factor binding-protein-3 (IGFBP-3). Best Pract Res Clin Endocrinol Metab, 29: 701–711. https://doi.org/10.1016/j.beem.2015.06.003

[15]

Drogan D, Schulze MB, Boeing H, et al., 2016, Insulin-like growth factor 1 and insulin-like growth factor-binding Protein 3 in relation to the risk of Type 2 diabetes mellitus: Results from the EPIC-potsdam study. Am J Epidemiol, 183: 553–560. https://doi.org/10.1093/aje/kwv188

[16]

Petta S, Camma C, Cabibi D, et al., 2011, Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 34: 757–766. https://doi.org/10.1111/j.1365-2036.2011.04788.x

[17]

Giordano M, DeFronzo RA, 1995, Acute effect of human recombinant insulin-like growth factor I on renal function in humans. Nephron, 71: 10–15. https://doi.org/10.1159/000188667

[18]

Hammerman MR, Miller SB, 1993, The growth hormone insulin-like growth factor axis in kidney revisited. Am J Physiol, 265: F1–F14. https://doi.org/10.1152/ajprenal.1993.265.1.F1

[19]

Jalalonmuhali M, Lim SK, Shah MN, et al., 2017, MDRD vs. CKD-EPI in comparison to (51)Chromium EDTA: A cross sectional study of Malaysian CKD cohort. BMC Nephrol, 18: 363. https://doi.org/10.1186/s12882-017-0776-2

[20]

Porrini E, Ruggenenti P, Luis-Lima S, et al., 2019, Estimated GFR: Time for a critical appraisal. Nat Rev Nephrol, 15: 177–19. https://doi.org/10.1038/s41581-018-0080-9

[21]

NeamTu M C, Avramescu ET, Marcu IR, et al., 2017, The correlation between insulin-like growth factor with glycemic control, glomerular filtration rate, blood pressure, hematological changes or body mass index in patients with Type 2 diabetes mellitus. Rom J Morphol Embryol, 58: 857–861.

[22]

Perticone F, Maio R, Sciacqua A, et al., 2009, Insulin-like growth factor-1 and glomerular filtration rate in hypertensive patients. J Hypertens, 27: 613–617. https://doi.org/10.1097/hjh.0b013e32831fda24

[23]

Lam CS, Chen MH, Lacey SM, et al., 2010, Circulating insulin-like growth factor-1 and its binding protein-3: Metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol, 30: 1479–1484. https://doi.org/10.1161/ATVBAHA.110.203943

[24]

Dittmann K, Wallaschofski H, Rettig R, et al., 2012, Association between serum insulin-like growth factor I or IGF-binding protein 3 and estimated glomerular filtration rate: Results of a population-based sample. BMC Nephrol, 13: 169. https://doi.org/10.1186/1471-2369-13-169

[25]

Frystyk J, Ivarsen P, Skjaerbaek C, et al., 1999, Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int, 56: 2076–2084. https://doi.org/10.1046/j.1523-1755.1999.00798.x

[26]

Bach LA, Hale LJ, 2015, Insulin-like growth factors and kidney disease. Am J Kidney Dis, 65: 327–336. https://doi.org/10.1053/j.ajkd.2014.05.024

[27]

Feld SM, Hirschberg R, Artishevsky A, et al., 1995, Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int, 48: 45–51. https://doi.org/10.1038/ki.1995.265

[28]

Vasylyeva TL, Chen X, Ferry RJ Jr, 2005, Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis. Growth Horm IGF Res, 15: 207–214. https://doi.org/10.1016/j.ghir.2005.02.008

[29]

Guler HP, Eckardt KU, Zapf J, et al., 1989, Insulin-like growth factor I increase glomerular filtration rate and renal plasma flow in man. Acta Endocrinol (Copenh), 121: 101–106. https://doi.org/10.1530/acta.0.1210101

[30]

Hirschberg R, Kopple JD, 1989, Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Invest, 83: 326–330. https://doi.org/10.1172/JCI113878

[31]

Moller J, 2003, Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res, 13: 55–74. https://doi.org/10.1016/s1096-6374(03)00011-x

[32]

Kamenicky P, Mazziotti G, Lombes M, et al., 2014, Growth hormone, insulin-like growth factor-1, and the kidney: Pathophysiological and clinical implications. Endocr Rev, 35: 234–281. https://doi.org/10.1210/er.2013-1071

[33]

Amit T, Youdim MB, Hochberg Z, 2000, Clinical review 112: Does serum growth hormone (GH) binding protein reflect human GH receptor function? J Clin Endocrinol Metab, 85: 927–932. https://doi.org/10.1210/jcem.85.3.6461

[34]

Kratzsch J, Keliner K, Zilkens T, et al., 1996, Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus. Clin Endocrinol (Oxf), 44: 673–678. https://doi.org/10.1046/j.1365-2265.1996.672494.x

[35]

Jorgensen JO, Pedersen SA, Thuesen L, et al., 1989, Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet, 1: 1221–1225. https://doi.org/10.1016/s0140-6736(89)92328-3

[36]

Miyauchi S, Miyake T, Miyazaki M, et al., 2019, Insulin-like growth factor-1 is inversely associated with liver fibrotic markers in patients with Type 2 diabetes mellitus. J Diabetes Investig, 10: 1083–1091. https://doi.org/10.1111/jdi.13000

[37]

Maximus PS, 2019, Insulin like growth factor 1 is linked to higher cardiovascular risk score in adults with Type 2 diabetes mellitus and chronic kidney disease. Diabetes Metab Syndr, 13: 2613–2618. https://doi.org/10.1016/j.dsx.2019.07.008

[38]

Sandhu MS, Heald AH, Gibson JM, et al., 2002, Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: A prospective observational study. Lancet, 359: 1740–1745. https://doi.org/10.1016/S0140-6736(02)08655-5

[39]

Simila ME, Kontto JP, Virtamo J, et al., 2019, Insulin-like growth factor I, binding proteins-1 and-3, risk of Type 2 diabetes and macronutrient intakes in men. Br J Nutr, 121: 938–944. https://doi.org/10.1017/S0007114519000321

[40]

Aleidi SM, Shayeb E, Bzour J, et al., 2019, Serum level of insulin-like growth factor-I in Type 2 diabetic patients: Impact of obesity. Horm Mol Biol Clin Investig, 39: 20190015. https://doi.org/10.1515/hmbci-2019-0015

[41]

Suda K, Matsumoto R, Fukuoka H, et al., 2016, The influence of Type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients. Growth Horm IGF Res, 29: 4–10. https://doi.org/10.1016/j.ghir.2016.03.002

[42]

Weil EJ, Kobes S, Jones LI, et al., 2019, Glycemia affects glomerular filtration rate in people with Type 2 diabetes. BMC Nephrol, 20: 397.

[43]

Barter P, Gotto AM, LaRosa JC, et al., 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 357: 1301–1310. https://doi.org/10.1056/NEJMoa064278

[44]

Kosmas CE, Martinez I, Sourlas A, et al., 2018, High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context, 7: 212525. https://doi.org/10.7573/dic.212525

[45]

Gordon DJ, Probstfield JL, Garrison RJ, et al., 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79: 8–15. https://doi.org/10.1161/01.cir.79.1.8

[46]

Teppala S, Shankar A, 2010, Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care, 33: 2257–2259. https://doi.org/10.2337/dc10-0770

[47]

Song X, Teng J, Wang A, et al., 2016, Positive correlation between serum IGF-1 and HDL-C in Type 2 diabetes mellitus. Diabetes Res Clin Pract, 118: 44–49. https://doi.org/10.1016/j.diabres.2016.04.056

[48]

Wang X, Tian F, Sun H, et al., 2019, Insulin-like growth factor-1 as a nutritional monitoring factor in patients with chronic intestinal failure. Clin Nutr, 38: 1737–1744. https://doi.org/10.1016/j.clnu.2018.07.031

Previous article in this issue

Next article in this issue

Global Translational Medicine, Electronic ISSN: 2811-0021 Print ISSN: 3060-8600, Published by AccScience Publishing